1. The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread.
- Author
-
Gomes, A. C., Baraniak, I. A., Lankina, A., Moulder, Z., Holenya, P., Atkinson, C., Tang, G., Mahungu, T., Kern, F., Griffiths, P. D., and Reeves, M. B.
- Subjects
CYTOMEGALOVIRUSES ,HUMAN cytomegalovirus ,ANTIBODY formation ,ANTIBODY titer ,IMMUNOGLOBULINS ,RECOMBINANT proteins ,VACCINES - Abstract
Vaccination against human cytomegalovirus (CMV) infection remains high priority. A recombinant form of a protein essential for CMV entry, glycoprotein B (gB), demonstrated partial protection in a clinical trial (NCT00299260) when delivered with the MF59 adjuvant. Although the antibody titre against gB correlated with protection poor neutralising responses against the 5 known antigenic domains (AD) of gB were evident. Here, we show that vaccination of CMV seronegative patients induces an antibody response against a region of gB we term AD-6. Responses to the polypeptide AD-6 are detected in >70% of vaccine recipients yet in <5% of naturally infected people. An AD-6 antibody binds to gB and to infected cells but not the virion directly. Consistent with this, the AD-6 antibody is non-neutralising but, instead, prevents cell-cell spread of CMV in vitro. The discovery of AD-6 responses has the potential to explain part of the protection mediated by gB vaccines against CMV following transplantation. A gB/MF59 vaccine candidate for human cytomegalovirus (HCMV) provided partial protection in organ transplant patients. Here, the authors identify antibody responses in trial participants that target virally infected cells to control cell-to-cell spread of HCMV, providing a potential mechanism for the observed protection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF